Using Artificial Intelligence to Predict CV Risk Assessment
It is well-established that patients with the highest proportion of visceral fat area are more likely to experience a heart attack or other cardiovascular event. While abdominal CT scans can provide a more granular look at body composition when routinely performed, ascertaining risk levels based on fat area is rarely done in clinical practice. Manually […]
SGLT-2 Inhibitor Empagliflozin Significantly Reduces CV Risk and Mortality in CV Outcomes Trial
Results of the EMPA-REG OUTCOME trial have shown that the SGLT2-inhibitor empagliflozin significantly reduced the risk of myocardial infarction, stroke, and CV death, as well as death from any cause, in more than 7000 adults with type 2 diabetes at high CV risk. Patients in the study were given either low- or high-dose empagliflozin or […]
SGLT-2 Inhibitor Reduces CV Risk and Shows Superiority in CV Outcomes Trial
Results of the EMPA-REG OUTCOME trial have shown that the SGLT2-inhibitor empagliflozin has met the primary cardiovascular (CV) outcomes endpoint and demonstrated superiority, reducing the risk of myocardial infarction, stroke, and CV death in more than 7000 adults with type 2 diabetes at high CV risk. Patients in the study were given either low- or […]
